NCT00147550 - MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

July 31, 2013

Conditions

MelanomaColonic NeoplasmsBreast Neoplasms

Interventions

DRUG

PD-0325901

Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.

Trial Locations (17)

10021

Pfizer Investigational Site, New York

10022

Pfizer Investigational Site, New York

33612

Pfizer Investigational Site, Tampa

35233

Pfizer Investigational Site, Birmingham

35294

Pfizer Investigational Site, Birmingham

44106

Pfizer Investigational Site, Cleveland

48201

Pfizer Investigational Site, Detroit

48202

Pfizer Investigational Site, Detroit

55905

Pfizer Investigational Site, Rochester

90025

Pfizer Investigational Site, Los Angeles

90404

Pfizer Investigational Site, Santa Monica

91942

Pfizer Investigational Site, La Mesa

92037

Pfizer Investigational Site, La Jolla

92093

Pfizer Investigational Site, La Jolla

92103

Pfizer Investigational Site, San Diego

92123

Pfizer Investigational Site, San Diego

35233-2115

Pfizer Investigational Site, Birmingham